Deferoxamine intranasal - Sanomune

Drug Profile

Deferoxamine intranasal - Sanomune

Alternative Names: SAN-121

Latest Information Update: 12 Nov 2016

Price : $50

At a glance

  • Originator HealthPartners Research Foundation
  • Developer Sanomune
  • Class Hydroxamic acids; Small molecules
  • Mechanism of Action Iron chelating agents
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

    No

Highest Development Phases

  • No development reported Alzheimer's disease

Most Recent Events

  • 20 Mar 2013 No development reported - Preclinical for Alzheimer's disease in USA (Intranasal)
  • 30 Jun 2010 Sanomune has been acquired by DiaMedica
  • 06 Mar 2009 Preclinical trials in Alzheimer's disease in USA (Intranasal)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top